Biofrontera AG
Notice of First Half Year Results 2015
Biofrontera AG / Biofrontera AG: Notice of First Half Year Results 2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Leverkusen, Germany, 04 August 2015 - Biofrontera AG (AIM: B8F), the European biopharmaceutical company, will be announcing its results for the first six months period ending 30 June 2015 on 14
August 2015.
There is a conference call for shareholders and interested investors on 14 August 2015 at the following times:
11.00am CET (10.00am GMT, 05.00am EST) conference call in German:
Dial-in number: +49 (0)69 271340166
02.00pm CET (01.00pm GMT, 08.00am EST) conference call in English:
Dial-in number Germany: Dial-in number UK: Dial-in number USA: |
+49 (69) 2713408001 +44 20336 45807 +1 240 645 0345 |
Conference Code: 33344902# (English conference call only)
Ends
Enquiries, please contact:
Biofrontera AG Prof. Hermann Lübbert, Chief Executive Officer Thomas Schaffer, Chief Financial Officer |
+49 (0) 214 87 63 2 0 press@biofrontera.com www.biofrontera.com |
|
IR Germany: Brainwell Asset Solutions Jürgen Benker |
+49 (0) 152 08931514 | |
Nomad and Broker: Shore Capital Bidhi Bhoma / Toby Gibbs |
+44(0) 20 7408 4090 | |
IR UK: Seton Services Toni Vallen |
+44(0) 20 7603 6797 | |
Financial PR: Gable Communications John Bick |
+44(0) 20 7193 7463 +44 (0)7872 061007 |
Background:
The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz® to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.
The company also markets the Belixos® dermatological range of cosmetics. Belixos® products contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos® cream, gel and scalp tonic are available through Amazon.
The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.
This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire
Lesen Sie auch
--- End of Message ---
Biofrontera AG
Hemmelrather Weg 201 Leverkusen Germany
WKN: 604611;ISIN: DE0006046113;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Bayerische Börse München,
Regulierter Markt in Frankfurter Wertpapierbörse,
Regulierter Markt in Börse Düsseldorf;